We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.25 | -4.88% | 4.875 | 4.75 | 5.00 | 5.125 | 4.875 | 5.125 | 630,501 | 14:14:21 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -1.09 | 5.61M |
From May 2022 to May 2024
By Kyle Morris
Shares in Genedrive PLC rose 15% on Wednesday after the company said that it has begun the process for regulatory approval for its MT-RNR1 ID Kit with the U.S. Food and Drug Administration.
The molecular-diagnostics company said the MT-RNR1 assay is a rapid point-of-care test to screen infants in urgent care for a genetic variant that could cause life-long hearing loss when carriers are given certain antibiotics.
Shares in Genedrive at 0721 GMT were up 1.60 pence at 12.60 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
October 05, 2022 03:38 ET (07:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Genedrive Chart |
1 Month Genedrive Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
